Market Cap: $8.57B
SI
Spyre Therapeutics, Inc.
SYRE
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $8.57B
Spyre Therapeutics (Ticker: SYRE) unveils promising results from its Phase 2 SKYLINE clinical trial for the treatment of ulcerative colitis, focusing on its investigational drug SPY002. The trial, whi…
Spyre Therapeutics (Ticker: SYRE) announces significant progress in its clinical research efforts focused on rheumatic diseases. SKYWAY Phase 2 Trial Enrollment Complete The company has successfully c…
Spyre Therapeutics (Ticker: SYRE) announces a pivotal expansion of its licensing agreement with Paragon Therapeutics, a move that significantly broadens the scope of its investigational drug, SPY003.…
Spyre Therapeutics announces a significant milestone in its Phase 2 SKYWAY trial, successfully completing enrollment for the rheumatoid arthritis cohort ahead of schedule. This progression presents an…
Spyre Therapeutics Navigates an Uncertain Economic Landscape in Biotech Sector In the wake of recent market volatility, Spyre Therapeutics focuses on strengthening its position within the biotechnolog…
Spyre Therapeutics Navigates Market Challenges Amid Economic Uncertainty In the current economic climate, biotech companies like Spyre Therapeutics face a unique set of challenges and opportunities th…